U
236.93
1.62 (0.69%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bullish | Bullish |
Biotechnology (Global) | Bullish | Bullish | |
Stock | United Therapeutics Corporation | - | - |
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Mid Value |
52 Weeks Range |
204.44 - 261.54
|
|
Price Target Range | ||
High | 330.00 (Leerink Partners, 39.28%) | Outperform |
Median | 308.00 (30.00%) | |
Low | 215.00 (Goldman Sachs, -9.26%) | Neutral |
Average | 295.60 (24.76%) | |
Total | 1 Neutral, 1 Buy, 2 Outperform, 1 Overweight |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Wells Fargo | 07 Mar 2024 | 325.00 (37.17%) | Overweight | 239.96 |
HC Wainwright & Co. | 22 Feb 2024 | 300.00 (26.62%) | Buy | 217.60 |
Wedbush | 22 Feb 2024 | 308.00 (30.00%) | Outperform | 217.60 |
Goldman Sachs | 12 Feb 2024 | 215.00 (-9.26%) | Neutral | 216.25 |
Leerink Partners | 05 Feb 2024 | 330.00 (39.28%) | Outperform | 212.76 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
DWEK RAYMOND | - | 234.57 | -6,000 | -1,407,420 |
ROTHBLATT MARTINE A | - | 235.32 | -28,800 | -6,777,216 |
Aggregate Net Quantity | -34,800 | |||
Aggregate Net Value ($) | -8,184,636 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 235.17 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
ROTHBLATT MARTINE A | Officer | 24 Apr 2024 | Automatic sell (-) | 3,600 | 237.00 | 853,200 |
ROTHBLATT MARTINE A | Officer | 24 Apr 2024 | Option execute | 3,600 | - | - |
ROTHBLATT MARTINE A | Officer | 23 Apr 2024 | Automatic sell (-) | 3,600 | 234.47 | 844,092 |
ROTHBLATT MARTINE A | Officer | 23 Apr 2024 | Option execute | 3,600 | - | - |
ROTHBLATT MARTINE A | Officer | 22 Apr 2024 | Automatic sell (-) | 3,600 | 234.06 | 842,616 |
ROTHBLATT MARTINE A | Officer | 22 Apr 2024 | Option execute | 3,600 | - | - |
DWEK RAYMOND | Director | 22 Apr 2024 | Automatic sell (-) | 3,000 | 234.06 | 702,180 |
DWEK RAYMOND | Director | 22 Apr 2024 | Option execute | 3,000 | - | - |
ROTHBLATT MARTINE A | Officer | 19 Apr 2024 | Automatic sell (-) | 3,600 | 237.93 | 856,548 |
ROTHBLATT MARTINE A | Officer | 19 Apr 2024 | Option execute | 3,600 | - | - |
ROTHBLATT MARTINE A | Officer | 18 Apr 2024 | Automatic sell (-) | 3,600 | 236.93 | 852,948 |
ROTHBLATT MARTINE A | Officer | 18 Apr 2024 | Option execute | 3,600 | - | - |
ROTHBLATT MARTINE A | Officer | 17 Apr 2024 | Automatic sell (-) | 3,600 | 235.31 | 847,116 |
ROTHBLATT MARTINE A | Officer | 17 Apr 2024 | Option execute | 3,600 | - | - |
ROTHBLATT MARTINE A | Officer | 16 Apr 2024 | Automatic sell (-) | 3,600 | 231.78 | 834,408 |
ROTHBLATT MARTINE A | Officer | 16 Apr 2024 | Option execute | 3,600 | - | - |
DWEK RAYMOND | Director | 15 Apr 2024 | Automatic sell (-) | 3,000 | 235.08 | 705,240 |
DWEK RAYMOND | Director | 15 Apr 2024 | Option execute | 3,000 | - | - |
ROTHBLATT MARTINE A | Officer | 15 Apr 2024 | Automatic sell (-) | 3,600 | 235.08 | 846,288 |
ROTHBLATT MARTINE A | Officer | 15 Apr 2024 | Option execute | 3,600 | - | - |
Show more |
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |